ArticleClinical pharmacology and therapeutics2026
Measuring the Impact of the Substitution of Innovator Biologics With Biosimilars on Uptake and Costs Among Ontario Public Drug Benefit Recipients.
Article in Clinical pharmacology and therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ten-Year Public Expenditure Savings Associated with TNF Inhibitor Biosimilars under Australia's Pharmaceutical Benefits Scheme.Clinical pharmacology and therapeutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In Ontario, biologics have historically represented a small proportion of public drug claims but a large proportion of spending. Biosimilars, lower cost alternatives to biologics, offer a potential solution to the rising spending on biologics. From March 2023 to January 2024, the Ontario Ministry of Health required public drug program beneficiaries on eight innovator biologics to transition to biosimilars. Clinicians were reimbursed for supporting patients who transitioned. To evaluate the impact of this biosimilar switch policy, we conducted a repeated cross-sectional study using administrative data from April 2019 to June 2024. For the biologics (innovator and biosimilar) included in the policy, we reported the biosimilar market share, public drug program spending, and clinician support fees. We used interrupted time series analyses to evaluate the policy's impact, and forecasting to estimate drug cost savings. From March 2023 to June 2024, the percentage of affected individuals on biosimilars increased from 21.7% to 96.5%. Drug cost savings were $65.2 million between April 2023 to June 2024, with most savings attributed to non-insulin biosimilars. We estimated savings of $46.6 million in Year 1 (April 2023 to March 2024) and $95.9 million in Year 2 (April 2024 to March 2025). Clinician support fees totaled $3.4 million across the study period. Ontario's biosimilar policy achieved high biosimilar uptake and substantial cost savings. Future research should examine the impact of this policy on clinical outcomes to assess its broader implications for patient care and long-term sustainability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.